199 related articles for article (PubMed ID: 16477627)
1. Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice.
Lacy J; Loomis R; Grill S; Srimatkandada P; Carbone R; Cheng YC
Int J Cancer; 2006 Jul; 119(2):309-16. PubMed ID: 16477627
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
3. Recombinant adeno-associated virus mediated RNA interference inhibits metastasis of nasopharyngeal cancer cells in vivo and in vitro by suppression of Epstein-Barr virus encoded LMP-1.
Li X; Liu X; Li CY; Ding Y; Chau D; Li G; Kung HF; Lin MC; Peng Y
Int J Oncol; 2006 Sep; 29(3):595-603. PubMed ID: 16865275
[TBL] [Abstract][Full Text] [Related]
4. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
5. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
6. ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts.
Hu ZY; Zhu XF; Zhong ZD; Sun J; Wang J; Yang D; Zeng YX
Int J Cancer; 2008 Nov; 123(10):2418-29. PubMed ID: 18712728
[TBL] [Abstract][Full Text] [Related]
7. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness ME; Kenney JL; Reiss M; Lacy J
Cancer Res; 2000 Oct; 60(19):5354-8. PubMed ID: 11034070
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
[TBL] [Abstract][Full Text] [Related]
10. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus.
Fan H; Nicholls J; Chua D; Chan KH; Sham J; Lee S; Gulley ML
Int J Cancer; 2004 Dec; 112(6):1036-41. PubMed ID: 15386346
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice.
Schlagbauer-Wadl H; Klosner G; Heere-Ress E; Waltering S; Moll I; Wolff K; Pehamberger H; Jansen B
J Invest Dermatol; 2000 Apr; 114(4):725-30. PubMed ID: 10733680
[TBL] [Abstract][Full Text] [Related]
12. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
13. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
Ramanarayanan J; Hernandez-Ilizaliturri FJ; Chanan-Khan A; Czuczman MS
Br J Haematol; 2004 Dec; 127(5):519-30. PubMed ID: 15566355
[TBL] [Abstract][Full Text] [Related]
14. [Effect of rAAV-mediated RNA interference against EB virus-encoded latent membrane protein 1 on nasopharyngeal carcinoma cell proliferation and metastasis in nude mice].
Liu X; Liu X; Li G; Zhang B; Wang L; Li XH; Li XP
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):611-4. PubMed ID: 19403376
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.
Wacheck V; Krepler C; Strommer S; Heere-Ress E; Klem R; Pehamberger H; Eichler HG; Jansen B
Antisense Nucleic Acid Drug Dev; 2002 Dec; 12(6):359-67. PubMed ID: 12568310
[TBL] [Abstract][Full Text] [Related]
16. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
Lopes de Menezes DE; Mayer LD
Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
[TBL] [Abstract][Full Text] [Related]
18. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells.
Mei YP; Zhou JM; Wang Y; Huang H; Deng R; Feng GK; Zeng YX; Zhu XF
Cell Cycle; 2007 Jun; 6(11):1379-85. PubMed ID: 17507800
[TBL] [Abstract][Full Text] [Related]
19. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
[TBL] [Abstract][Full Text] [Related]
20. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
Yip KW; Mocanu JD; Au PY; Sleep GT; Huang D; Busson P; Yeh WC; Gilbert R; O'Sullivan B; Gullane P; Bastianutto C; Liu FF
Clin Cancer Res; 2005 Nov; 11(22):8131-44. PubMed ID: 16299246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
